慢性髓系白血病靶向治疗中抗血管新生药物应用研究
|
摘要
目的探讨抗血管新生药物在慢性髓系白血病靶向治疗中的应用价值。方法本次研究将我院2013年6月~2014年8月收治的48例慢性髓系白血病患者分为研究组和一般组,予以一般组伊马替尼治疗,在一般组的基础上予以研究组重组人血管内皮抑制素治疗。结果治疗2个疗程后,研究组的治疗总有效率为87.5%,高于一般组的62.5%(P<0.05)。治疗3个疗程后,研究组的治疗总有效率为95.8%,高于一般组的66.8%(P<0.01)。治疗结束后随访1年,研究组的病死率为16.7%,低于一般组的50.0%(P<0.05)。结论抗血管新生药物在慢性髓系白血病患者靶向治疗中的应用,可有效改善患者临床治疗效果和预后。
Objective To investigate the application value of anti angiogenesis drugs in the treatment of chronic myeloid leukemia. Methods 48 cases of patients with chronic myeloid leukemia in our hospital from June 2013 to August 2014 were divided into study group and general group, which were treated with imatinib in general group. Results After 2 courses of treatment, the total effective rate was 87.5% in the study group, which was higher than that in the general group of 62.5%(P<0.05). After 3 courses of treatment, the total effective rate of the study group was 95.8%, which was significantly higher than that of the general group(P<0.01). At the end of the treatment, two groups of patients were followed up for 1 years, the mortality rate of the study group was 16.7%, lower than the general group of 50%(P<0.05). Conclusion The application of anti angiogenesis drugs in the treatment of patients with chronic myeloid leukemia can effectively improve the clinical therapeutic effect and prognosis.
Objective To investigate the application value of anti angiogenesis drugs in the treatment of chronic myeloid leukemia. Methods 48 cases of patients with chronic myeloid leukemia in our hospital from June 2013 to August 2014 were divided into study group and general group, which were treated with imatinib in general group. Results After 2 courses of treatment, the total effective rate was 87.5% in the study group, which was higher than that in the general group of 62.5%(P<0.05). After 3 courses of treatment, the total effective rate of the study group was 95.8%, which was significantly higher than that of the general group(P<0.01). At the end of the treatment, two groups of patients were followed up for 1 years, the mortality rate of the study group was 16.7%, lower than the general group of 50%(P<0.05). Conclusion The application of anti angiogenesis drugs in the treatment of patients with chronic myeloid leukemia can effectively improve the clinical therapeutic effect and prognosis.
引文
[1]周玫,欧阳晨曦.白血病干细胞表面分子、调控机制及微环境的靶向治疗[J].中国组织工程研究与临床康复,2010,14(32):6048-6051.
[2]任思楣,张砚君,彭洪薇,等.靶向白血病干细胞CD123的毒性融合蛋白的制备[J].白血病·淋巴瘤,2011,20(8):490-493.
[3]崔鹤,张王刚.抗CD123抗体靶向治疗急性髓系白血病[J].现代肿瘤医学,2015,23(10):1460-1463.
[4]石丽芳.Notch信号在白血病中的作用机制与靶向治疗[J].医学综述,2011,17(10):1475-1478.
[5]姜国胜.造血系统恶性肿瘤的定向诱导分化和靶向治疗[J].中国肿瘤生物治疗杂志,2010,17(6):589-596.
[6]席晓平,刘华胜.纳米微泡载药靶向治疗中枢神经系统白血病的研究进展[J].中国实验血液学杂志,2014,22(3):879-882.
[7]苏萌.白血病靶向治疗的研究进展[J].国际儿科学杂志,2014,41(3):270-273.
[8]王颖超,冯磊,殷楚云,等.抗CD47抗体联合阿糖胞苷靶向治疗NOD/SCID小鼠单核细胞白血病的研究[J].中国当代儿科杂志,2013,15(7):577-582.
[9]王钿钿,陈宝安.白血病干/祖细胞及靶向治疗研究进展[J].中国实验血液学杂志,2010,18(6):1654-1658.
[2]任思楣,张砚君,彭洪薇,等.靶向白血病干细胞CD123的毒性融合蛋白的制备[J].白血病·淋巴瘤,2011,20(8):490-493.
[3]崔鹤,张王刚.抗CD123抗体靶向治疗急性髓系白血病[J].现代肿瘤医学,2015,23(10):1460-1463.
[4]石丽芳.Notch信号在白血病中的作用机制与靶向治疗[J].医学综述,2011,17(10):1475-1478.
[5]姜国胜.造血系统恶性肿瘤的定向诱导分化和靶向治疗[J].中国肿瘤生物治疗杂志,2010,17(6):589-596.
[6]席晓平,刘华胜.纳米微泡载药靶向治疗中枢神经系统白血病的研究进展[J].中国实验血液学杂志,2014,22(3):879-882.
[7]苏萌.白血病靶向治疗的研究进展[J].国际儿科学杂志,2014,41(3):270-273.
[8]王颖超,冯磊,殷楚云,等.抗CD47抗体联合阿糖胞苷靶向治疗NOD/SCID小鼠单核细胞白血病的研究[J].中国当代儿科杂志,2013,15(7):577-582.
[9]王钿钿,陈宝安.白血病干/祖细胞及靶向治疗研究进展[J].中国实验血液学杂志,2010,18(6):1654-1658.